See every side of every news story
Get Started
SubscribeLogin
Everton
Donald Trump
Ukraine War
Volodymyr Zelenskyy
Viktor Orbán
Hamas
Basketball
Israel-Hamas Conflict
Manchester United
Elon Musk
Premier League
Soccer
Published • loading... • Updated

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Summary by Financial Post
PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque pso…

4 Articles

All
Left
Center
Right
1
Financial PostFinancial Post

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque pso…

·Canada
Read Full Article
hcplive.comhcplive.com

New Biosimilar, Ustekinumab-aekn, Now Available in U.S.

Alvotech and Teva announced that the biosimilar will be interchangeable with the reference after ustekinumab-auub’s exclusivity expires in April 2025.

Read Full Article
CDR – Chain Drug ReviewCDR – Chain Drug Review

SELARSDI, biosimilar to Stelara, rolls out in U.S.

PARSIPPANY, N.J. – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Alvotech has announced the availability of SELARSDI (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. mark…

Read Full Article
ADKhabarADKhabar

Teva and Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available in the U.S.

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI SELARSDI is the second biosimilar to launch in the U.S. under the Teva and Alvotech strategic partnership, which includes nine products SELARSDI is approved […]

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Financial Post broke the news in Canada on Friday, February 21, 2025.
Sources are mostly out of (0)

Similar News Topics

Leonardo Da Vinci

Leonardo Da Vinci

United States

United States

News
For You
Search
BlindspotLocal